November 6, 2024, Shanghai - At the 7th China International Import Expo, Shanghai Dunwill Medical Technology Development Co., Ltd. (hereinafter referred to as "Dunhui Medical"), Zhongshan Hospital Fudan University (hereinafter referred to as "Zhongshan Hospital"), and Roche Diagnostics jointly announced that they will work together to promote NGS (Next Generation Sequencing) digital pathology cooperation, create a "Sample in, Result out" full process automated NGS detection solution based on local translational needs, and promote clinical research, technological innovation, and scientific research results, jointly promoting high-quality development in the field of precision medicine.

Tang Qiqun, Assistant Dean and Executive Dean of the Clinical Medicine Research Institute of Zhongshan Hospital Fudan University, Hou Yingrong, Director of the Pathology Department of Zhongshan Hospital Fudan University, Yao Guoliang, General Manager of Roche Diagnostics China, Wang Feng, Senior Director of Roche Diagnostics China - Life Sciences Department, Wen Dong, Founder and Chairman of Shanghai Dunwill Medical Technology Development Co., Ltd., and Hou Ying, Executive Director of the Market and Strategic Development Center of Shanghai Dunwill Medical Technology Development Co., Ltd., attended the launch ceremony together.

Accelerating Clinical Translation, NGS Digitization is Imperative

NGS technology is the core tool of modern genomics and personalized medicine. Because of its high flux, low cost and broad application prospects, it has greatly promoted the development of precision medicine. At present, it has been widely used in genetic disease screening, prenatal testing, tumor diagnosis and treatment, detection of infectious diseases pathogens and other fields. With the gradual improvement of policies and technological advancements, NGS is playing an increasingly important role in precision medicine and personalized medicine. However, due to the complexity of data processing and the requirement for high precision and speed, the implementation and transformation of NGS technology still face enormous challenges. Therefore, achieving automation, digitization, and intelligence of NGS technology is not only an inevitable trend in technological development, but also an urgent call for clinical needs.

The whole process automated NGS solution is the result of Roche Diagnostics' deep cultivation in the Chinese market. Relying on its rich experience and innovative technology in the sequencing field, together with the local innovative translational enterprise - Dunwill Medical, it further iterates and comprehensively upgrades the NGS's digital and intelligent overall solution of "Sample in, Result out", and creates a new model of localized cooperation that meets China's clinical analysis and application needs. Hou Ying, Executive Director of Dunwill Medical Market and Strategic Development Center, said, "Dunwill Medical has rich experience in the exploration of original research biomarkers and the development of in vitro diagnostic reagents. In the new era of promoting high-quality development of the industry through the development of new quality productivity advocated by the country, we hope to effectively bridge the profound insights of Zhongshan Hospital as a national medical center in complex diseases with Roche Diagnostics' globally leading laboratory overall solution technology platform. With clinical needs as the core, we will accelerate the clinical translation of relevant scientific research achievements and standardize the practice of new applications, and actively explore new paradigms for China's medical research and production closed-loop practice.

"Sample in, Result out" , Explore a New Chapter in Local Solutions

At CIIE, Zhongshan Hospital, Roche Diagnostics, and Dunwill Medical jointly launched a cooperation on NGS intelligent pathology. Roche Diagnostics' advanced platform and Dunwill's innovative translational plan will further empower Zhongshan Hospital's smart hospital development and achievement transformation under high-quality development. Tang Qiqun, Assistant to the President of Zhongshan Hospital and Executive Director of the Clinical Medical Research Institute, said, "Zhongshan Hospital has always adhered to the concept of 'patient-centered, disease centered', attaches great importance to cooperation between the hospital and enterprises, and promotes high-quality development of the hospital. Zhongshan Hospital will rely on the technological advantages of Roche Diagnostics and Dunwill Medical to jointly tackle medical transformation projects, build digital and intelligent pathology construction, accelerate clinical research, technological innovation, and the landing and transformation of scientific research results, and lead the high-quality development of precision medicine.

As a global leader in in in vitro diagnostics, Roche Diagnostics has a deep technological accumulation and innovative strength in the NGS field. Its fully automated sequencing library preparation system AVENIO Edge System achieves automated operations from sample preparation to data processing, providing strong support for scientific research and clinical application translation. Adhering to the spirit of open cooperation, Roche Diagnostics looks forward to complementing the advantages of its Chinese partners and working together to promote innovative development in precision medicine.

Wang Feng, Senior Director of Life Sciences at Roche Diagnostics China, said, "We are honored to have partnered with Zhongshan Hospital and Dunwill Medical to combine the fully automated NGS testing solution with clinical application needs. This is another important milestone in Roche Diagnostics' localization cooperation. In the future, we will continue to uphold the concept of 'in China, for China', continuously strengthen close cooperation with local partners, and jointly promote the innovation and application of NGS technology, contribute more wisdom and strength to the development of precision medicine, and bring benefits to more patients.